Agreement gives lower-income nations access to HIV prevention drug

A new agreement will allow lower-income countries to access the HIV prevention drug lenacapavir, a "game-changer" for global health equity. The Global Fund and Gilead signed the deal to provide lenacapavir to low- and middle-income countries, including South Africa, where adolescent girls are disproportionately affected by HIV. The drug, requiring only two injections per year, has shown over 99.9% effectiveness. The Global Fund aims to reach two million people with lenacapavir, hoping to deliver the first shipments to at least one African country by the end of 2025. This marks a shift in HIV prevention.